Pressure Sensitive Adhesive Means Patents (Class 424/448)
-
Patent number: 7087241Abstract: The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder.Type: GrantFiled: October 7, 2005Date of Patent: August 8, 2006Assignee: Watson Laboratories, Inc.Inventors: Steven W. Sanders, Charles D. Ebert
-
Patent number: 7081251Abstract: The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder.Type: GrantFiled: December 8, 2003Date of Patent: July 25, 2006Assignee: Watson Laboratories, Inc.Inventors: Steven W. Sanders, Charles D. Ebert
-
Patent number: 7081252Abstract: The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder.Type: GrantFiled: December 8, 2003Date of Patent: July 25, 2006Assignee: Watson Laboratories, Inc.Inventors: Steven W. Sanders, Charles D. Ebert
-
Patent number: 7081250Abstract: The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder.Type: GrantFiled: December 8, 2003Date of Patent: July 25, 2006Assignee: Watson Laboratories, Inc.Inventors: Steven W. Sanders, Charles D. Ebert
-
Patent number: 7081249Abstract: The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder.Type: GrantFiled: December 8, 2003Date of Patent: July 25, 2006Assignee: Watson Laboratories, Inc.Inventors: Steven W. Sanders, Charles D. Ebert
-
Patent number: 7076282Abstract: Bioadhesive Compositions which comprise a hydrophobic polymer wherein the concentration of the polymer at the surface of the adhesive is greater than its concentration in the bulk of the adhesive are described; and biomedical electrodes, fixation products and wound dressings containing them.Type: GrantFiled: October 29, 2002Date of Patent: July 11, 2006Assignee: First Water LimitedInventors: Hugh Semple Munro, Mohammed Yasin
-
Patent number: 7070808Abstract: Transdermal drug delivery patches and methods of their production are described. The patches can be made such that the accommodate highly plasticizing drugs such as selegiline and/or the use of protonated forms of various drugs.Type: GrantFiled: January 5, 2001Date of Patent: July 4, 2006Assignee: Mylan Technologies, Inc.Inventors: Sharad K. Govil, Ludwig J. Weimann
-
Patent number: 7063859Abstract: A transdermal drug delivery device for topical application of active agents is disclosed. The invention comprises the use of a flexible and soft backing layer, in particular a cellular foam, having an inner surface and an outer surface, wherein an impermeable polymeric barrier film is affixed to its inner surface. The barrier film functions to anchor and support an active agent carrier composition disposed thereon, and to prevent passage of such composition into the backing layer. The system provides excellent flexibility and conformability for topical application to sites subject to frequent movement or which are greatly contoured. Methods of use are also disclosed.Type: GrantFiled: September 18, 2002Date of Patent: June 20, 2006Assignee: Noven Pharmaceuticals, Inc.Inventors: David Kanios, Juan A. Mantelle, David Houze
-
Patent number: 7056526Abstract: The present invention provides a medical adhesive tape and a tape preparation for percutaneous absorption, both having an adhesive layer that resists glue remainder and stickiness upon peeling off of the tape even after adhesion to the human skin for a long time, and a medical adhesive composition to be used for such tapes. The medical adhesive composition of the present invention includes, as essential elements, (A) a copolymer containing (a) alkyl (meth)acrylate, wherein the alkyl moiety has 4 to 18 carbon atoms, in a proportion of not less than 50 wt % of the copolymer and (b) a carboxyl group-containing vinyl compound in a proportion of 0.1 wt %–10 wt % of the copolymer, (B) an alkoxide or a chelate compound of at least a metal selected from titanium, zirconium, zinc and aluminum, and (C) a polyol compound in a proportion of 0.2 wt %–5 wt % of the aforementioned medical adhesive composition.Type: GrantFiled: August 29, 2002Date of Patent: June 6, 2006Assignee: Nitto Denko CorporationInventors: Hidetoshi Kuroda, Takateru Muraoka, Keigo Inosaka, Hitoshi Akemi
-
Patent number: 7056528Abstract: A transdermal therapeutic system comprising a largely water vapor-impermeable backing layer, at least one active substance-containing matrix layer comprising the active substance tulobuterol, as well as a removable protective layer, is characterized in that said matrix is built-up on the basis of polyacrylate pressure-sensitive adhesives and contains tulobuterol in the form of its salt tulobuterol hydrochloride as active substance.Type: GrantFiled: October 6, 2000Date of Patent: June 6, 2006Assignee: LTS Lohmann Therapie-Systeme AGInventor: Stefan Bracht
-
Patent number: 7056527Abstract: A patch comprising an adhesive layer formed on one surface of a flexible support, wherein said adhesive layer containing a drug, an absorption enhancer and an adhesive comprising; (i) said drug is buprenorphine hydrochloride and/or buprenorphine, and (ii) said absorption enhancer is a mixture of polyoxyethylene sorbitan mono fatty acid ester having 6 to 20 of oxyethylene units and 12 to 18 of carbon number of fatty acid ester, and at least one selected from the group consisting of liquid higher fatty acid ester, 60 to 180 of molecular weight of liquid poly hydric alcohol, lactic acid and triacetin, and (iii) said adhesive is an acrylic-based adhesive.Type: GrantFiled: February 22, 2001Date of Patent: June 6, 2006Assignee: Teijin LimitedInventors: Susumu Maruo, Osafumi Hidaka, Satoshi Murakami
-
Patent number: 7052714Abstract: Ophthalmic adhesive preparations for percutaneous absorption to be used in treating diseases in the posterior parts of eye characterized by having a drug-containing layer which contains a drug to be delivered to the posterior parts of eye including the crystalline lens, the vitreous body, the uvea and the retina, together with a percutaneous sorbefacient comprising polyoxyethylene oleyl ether and/or isopropyl myristate uniformly dispersed in a base matrix.Type: GrantFiled: September 29, 2000Date of Patent: May 30, 2006Assignees: Senju Pharmaceutical Co., LTD, Kakuji TojoInventors: Kakuji Tojo, Akiharu Isowaki
-
Patent number: 7045145Abstract: A transdermal contraceptive delivery system (TCDS) for fertility control in women is described. It comprises a backing layer, an adjoining layer of a solid absorption adhesive polymer matrix in which effective daily doses of an estrogen and a progestin are dispersed and released for transdermal absorption. Presently preferred is the use of the synthetic estrogen, ethinyl estradiol, and the synthetic progestin, levonorgestrel. Along with these two steroidal contraceptive agents, a combination of several chemical skin permeation enhancing agents, including capric acid, blended at specific weight ratios, ranging from 2:1:1:0.8 to 6:1:1:0.8, are homogeneously dispersed in the adhesive polymer matrix. The invention also provides a method of fertility control utilizing the transdermal contraceptive delivery system.Type: GrantFiled: November 22, 2000Date of Patent: May 16, 2006Assignee: Agile Therapeutics, Inc.Inventor: Te-Yen Chien
-
Patent number: 7045144Abstract: The invention relates to a plaster containing an active agent, comprising at least one cover membrane and an active membrane which is based on a skin-compatible matrix containing a molecular sieve which is loaded with at least one active agent. The molecular sieve/active agent adduct releases the active agent when the active membrane comes into contact with the skin, in conjunction with the transpired water of the skin. The inventive plaster is characterised in that the molecular sieve/active agent adduct also contains water of crystallisation, to the extent that the molecular sieve is partially hydrated compared to a sufficient basic molar quantity (m) of water of crystallisation, the molecular sieve with the reduced molar quantity (m?) of water of crystallisation being loaded with the active agent (Z, Z1, Z2) so that when the active membrane comes into contact with the skin, water is absorbed and the active agent is desorbed, whereupon the water of crystallisation content of the molecular sieve increases.Type: GrantFiled: February 23, 2001Date of Patent: May 16, 2006Assignee: Intech Thüringen GmbHInventors: Werner Schunk, Michael Bruder, Konrad Giessmann, Karl-Heinz Krause, Gerhard Merkmann
-
Patent number: 7029694Abstract: The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder. In some aspects, the composition may be presented in the form of an unoccluded or free form topically administered gel.Type: GrantFiled: November 1, 2002Date of Patent: April 18, 2006Assignee: Watson Laboratories, Inc.Inventors: Charles D. Ebert, Steven W. Sanders
-
Patent number: 7018648Abstract: The invention relates to a self-adhesive transdermal device for the administration of testosterone and/or at least one of the derivatives thereof, comprising successively at least one support layer, a self-adhesive matrix layer and a detachable protective layer, whereby the matrix layer comprises at least one self-adhesive polymer, at least one formulating adjuvant for the matrix layer, at least one solvent chosen from the group made up of solvents of testosterone or the derivatives thereof and testosterone and/or at least one of the derivatives thereof in an oversaturated solution. The device has excellent testosterone permeation qualities and excellent cutaneous tolerance and adhesion qualities. The invention also relates to a method for the production of said device and the use thereof for a medicament, i.e. within the framework of a testosterone replacement therapy.Type: GrantFiled: May 18, 2000Date of Patent: March 28, 2006Assignee: Pierre Fabre MedicamentInventors: Michel Sournac, Laurent Liorzou, Joël Bougaret
-
Patent number: 7018622Abstract: A peroxide product is provided. The peroxide product includes a package having a headspace, a substrate disposed within the package, and a thin layer of a composition having a peroxide active and a polyol, wherein the thin layer is disposed adjacent the substrate. The peroxide product also includes at least one means for increasing the stability of the peroxide active of the composition. The thin layer of the composition has at least about 43% of its original concentration of the peroxide active at twelve months after manufacture when stored at about 25° C. and in the absence of light.Type: GrantFiled: October 24, 2002Date of Patent: March 28, 2006Assignee: The Procter & Gamble CompanyInventors: Lesle Marie Goodhart, Sue Ellen Bernheim, Paul Albert Sagel, Christopher Scott Ralston, Gary Lyle Walden, Hooman Shahidi, Richard Joseph Sunberg
-
Patent number: 7018649Abstract: A method of effectively treating hypertension in humans is achieved by administering felodipine via a transdermal formulation. Preferably, the transdermal formulation is applied to the skin of the patient and maintained in contact with the skin for at least about 24 hours days, and preferably for about 3 to about 8 days.Type: GrantFiled: October 23, 2001Date of Patent: March 28, 2006Assignee: Euro-Celtique, S.A.Inventors: Lino Tavares, Ihor Shevchuk, Mark Alfonso, Geraldine Marcenyac, Kirti Valia
-
Patent number: 7018647Abstract: In order to provide an external skin patch having improved painkilling effect for pains accompanied by inflammation, such as chronic arthrorheumatism, arthrosis deformans or low back pain, an external skin patch is obtained by coating a drug-containing base on a substrate; the drug-containing base comprises an adhesive gel base containing a water soluble polymeric material, a crosslinking agent, water and a humectant as essential components, and a local anesthetic and a nonsteroidal antiphlogistic analgesic agent as medicinal components.Type: GrantFiled: October 25, 2000Date of Patent: March 28, 2006Assignee: Teikoku Seiyaku Co., LTDInventors: Keiko Yamasaki, Mitsuji Akazawa, Jutaro Shudo, Keiji Nozaki
-
Patent number: 7011843Abstract: A method for the protection of a human being against any health impairment as a result of the ingestion of the whole or parts of a transdermal therapeutic system containing at least one pharmacologically active ingredient, which is toxic or induces nausea or addiction at oral, but not at transdermal administration is disclosed. The method comprises adding to said transdermal therapeutic system a substance being able to keep off a human being from said ingestion.Type: GrantFiled: May 21, 2002Date of Patent: March 14, 2006Assignee: LTS Lohmann-Therapie Systeme AGInventors: Frank Becher, Ann-Katrin Klink
-
Patent number: 7008647Abstract: The invention relates to the use of one or more antimicrobial metals selected from silver, gold, platinum, and palladium but most preferably silver, preferably formed with atomic disorder, and preferably in a nanocrystalline form, for the treatment of a acne. The nanocrystalline antimicrobial metal of choice may be used in the form of a nanocrystalline coating of one or more antimicrobial metals, a nanocrystalline powder of one or more antimicrobial metals, or a solution containing dissolved species from a nanocrystalline powder or coating of one or more antimicrobial metals.Type: GrantFiled: April 23, 2001Date of Patent: March 7, 2006Assignee: Nucryst Pharmaceuticals Corp.Inventors: Robert Edward Burrell, Hua Qing Yin
-
Patent number: 7004321Abstract: The invention relates to a packaging of products which are additionally packed in a pouch (2) in order to protect the same, whereby the packaging is comprised of at least two pouches. The products placed in these pouches can be identical or different. These products are to be preferably removed and used in a predetermined order.Type: GrantFiled: March 9, 2000Date of Patent: February 28, 2006Assignee: LTS Lohmann Therapie-Systeme AGInventors: Detlef Palm, Ronald Hackbarth, Michael Heberle, Detlev Neuland
-
Patent number: 7001613Abstract: An active substance matrix patch for controlled delivery of at least one hyperemic active substance to the skin, comprising a flexible cover layer and a water insoluble, pressure sensitive adhesive active substance matrix, wherein said adhesive matrix is free from mineral oils and tackifier resins and comprising: a) from 25 to 90% by weight of synthetic framework polymers based on polyisobutylene, b) from 5 to 40% by weight of amorphous poly-?-olefin, c) from 10 to 60% by weight of an insoluble hydrophilic filler having an average particle size of less than 100 ?m, and d) from 0.001 to 20% by weight of the hyperemic active substance.Type: GrantFiled: May 12, 2003Date of Patent: February 21, 2006Assignee: Beiersdorf AGInventors: Detlev Radloff, Matthias Wasner
-
Patent number: 6998138Abstract: The present invention provides a topical drug delivery system which comprises: a therapeutically effective amount of an anti-alopecia agent; at least one dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen ester; and a volatile liquid. The invention also provides a method for administering at least one systemic acting anti-alopecia agent to an animal which comprises applying an effective amount of the anti-alopecia agent in the form of the drug delivery system of the present invention.Type: GrantFiled: August 8, 2003Date of Patent: February 14, 2006Assignee: Acrux DDS Pty. Ltd.Inventors: Nora Yat Knork Chew, Barry Leonard Reed, Timothy Matthias Morgan, Barrie Charles Finnin
-
Patent number: 6992233Abstract: A delivery system for the delivery of flowable medicinal, therapeutic or medicine materials has a strip with flowable material contained and restrained therein. A removable seal is provided, so that when the removable seal is removed, the flowable material will flow from a storage area onto a site selected for treatment. The removable seal may be provided with additional features such as absorbent coatings, or additional disinfectants coatings useful in preparing the wound surface to receive the flowable wound treatment material. A preferred composition is a system, article and method for the enhancement of clotting in wounds with extravascular blood flow, especially where the surface of the tissue has been broken.Type: GrantFiled: May 31, 2002Date of Patent: January 31, 2006Assignee: MedaFor, Inc.Inventors: James Franklin Drake, Mark Harold Ereth, Lynn R. Skow
-
Patent number: 6974588Abstract: A transdermal patch for administering a volatile liquid drug, such as nicotine, transdermally to a patient comprising a four-layer laminated composite of: a top drug impermeable backing layer; a pressure sensitive silicone adhesive layer containing the drug; a pressure sensitive acrylic adhesive layer also containing the drug; and a removable siliconized release liner layer. Also disclosed is a method for treating a person for nicotine dependence and particularly for treating a woman for nicotine dependence.Type: GrantFiled: December 7, 1999Date of Patent: December 13, 2005Assignee: Elan Pharma International LimitedInventors: Jesus Miranda, Charles J. Betlach, II
-
Patent number: 6964777Abstract: The present invention provides a transdermal drug delivery system which comprises: a therapeutically effective amount of an antianxiety agent; at least one dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen ester; and at least one volatile liquid. The invention also provides a method for administering at least one systemic acting antianxiety agent to an animal which comprises applying an effective amount of the antianxiety agent in the form of the drug delivery system of the present invention.Type: GrantFiled: May 2, 2003Date of Patent: November 15, 2005Assignee: Acrux DDS PTY LTDInventors: Kathryn Traci-Jane Klose, Ennio La Guardia, Timothy Matthias Morgan, Barrie Charles Finnin, Barry Leonard Reed
-
Patent number: 6962691Abstract: A topical, medicinal spray composition is provided comprising a drug or combination of drugs in a carrier which, when sprayed on a surface, forms a film. The composition comprises at least one medicament, at least one film former and at least one vehicle. The composition of the invention may further comprise at least one permeation enhancer, at least one solubilizer, at least one plasticizer, and at least one water soluble additive. A metered dose of the composition can be sprayed on a topical site to form a stable, breathable film, preferably over a fixed surface area. A wide range of medicaments for human and veterinary use may be present that act locally or transdermally.Type: GrantFiled: February 15, 2000Date of Patent: November 8, 2005Assignee: U & I Pharmaceuticals Ltd.Inventors: Amar Lulla, Geena Malhotra, Preeti Raut
-
Patent number: 6953590Abstract: A preparation for transdermal absorption is disclosed which is suited for alleviating lasting pains caused by herpes zoster or postherpetic neuralgia and is practical and more improved in drug efficacy, safety and application characteristics. This tape preparation for transdermal absorption is obtained by causing an adhesive mass prepared by incorporating 1–30 parts by weight of a local anesthetic as an active ingredient in 100 parts by weight of a nonaqueous adhesive mass base comprising 5–50% by weight of a styrene-isoprene-styrene block copolymer, 1–60% by weight of an alicyclic saturated hydrocarbon resin, 5–60% by weight of liquid paraffin and 1–30% by weight of butyl rubber to be supported on a backing.Type: GrantFiled: September 9, 1999Date of Patent: October 11, 2005Assignees: Yutoku Pharmaceutical Ind. Co., Ltd., Maruho Kabushiki KaishaInventors: Yukino Owaki, Michiyo Hashimoto, Isamu Sakamoto, Kunio Takiguchi, Yoetsu Toyoshima
-
Patent number: 6946142Abstract: The present invention relates to a dry type teeth whitening patch with a multi-layer structure of three or more layers. More particularly, in the dry type patch, a contact adhesive layer substantially free of peroxide comprises a hydrophilic glass polymer as a base polymer so that it provides substantial adhesive strength when hydrated by water, an active material reservoir layer comprises peroxide as a teeth whitening agent, and a backing layer which is impermeable to water. The dry type patch of the present invention has superior teeth whitening effect and excellent peroxide stability at a high temperature since the peroxide-containing layer is covered and protected by other layers.Type: GrantFiled: June 20, 2002Date of Patent: September 20, 2005Assignee: LG Household & Healthcare Ltd.Inventors: Sug-Youn Chang, Ji-Young Kim, Jong-Ho Kim, Sei-Young Yun
-
Patent number: 6942875Abstract: A method of treating or preventing skin yeast infections, such as cutaneous candidiasis, includes applying a polymerizable monomer adhesive composition to an area of skin afflicted with or susceptible to a skin yeast infection, optionally with at least one of an additional anti-fungal agent or a skin care additive, and allowing the polymerizable monomer composition to polymerize to form a polymer film over the area of skin.Type: GrantFiled: July 5, 2001Date of Patent: September 13, 2005Assignee: Closure Medical CorporationInventor: Daniel L. Hedgpeth
-
Patent number: 6929801Abstract: The present invention provides a transdermal drug delivery system which comprises: a therapeutically effective amount of an antiParkinson agent; at least one dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen ester; and at least one volatile liquid. The invention also provides a method for administering at least one systemic acting antiParkinson agent to an animal which comprises applying an effective amount of the antiParkinson agent in the form of the drug delivery system of the present invention.Type: GrantFiled: May 2, 2003Date of Patent: August 16, 2005Assignee: Acrux DDS PTY LTDInventors: Kathryn Traci-Jane Klose, Ngan Thi Kim Tran, Timothy Matthias Morgon, Barrie Charles Finnin, Barry Leonard Reed
-
Patent number: 6926904Abstract: A cosmetic product system is provided which includes a cosmetic composition for combating signs of aging, and a test device packaged with the composition. The device includes a mechanism for evaluating progress of the combat against the signs of aging occurring over a period of time within which the composition is applied to an area of skin being monitored.Type: GrantFiled: October 29, 2001Date of Patent: August 9, 2005Assignee: Unilever Home & Personal Care USA, division of Conopco, Inc.Inventors: Craig Stephen Slavtcheff, Liam Anthony Murray, Josephine Telesca, Robert Edward Gott
-
Patent number: 6923982Abstract: A calendered hydrocolloid dressing for the wound care and a one step method of manufacturing the hydrocolloidal dressing are described. In particular, the invention is concerned with a hydrocolloid dressing which is absorbent, non-damaging to the skin and comfortable to the user preferably having at least a thermoplastic elastomer backing and water absorbent polymeric adhesive layer.Type: GrantFiled: August 8, 2001Date of Patent: August 2, 2005Assignee: Scapa North AmericaInventors: Scott C. Barnes, Jim Jian Ling Ding
-
Patent number: 6923983Abstract: The present invention provides a transdermal drug delivery system which comprises: a therapeutically effective amount of a hormone; at least one dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen ester; and at least one volatile liquid.Type: GrantFiled: May 2, 2003Date of Patent: August 2, 2005Assignee: Acrux DDS PTY LTDInventors: Timothy Matthias Morgan, Margarita Vladislavova Bakalova, Karthryn Traci-Jane Klose, Barrie Charles Finnin, Barry Leonard Reed
-
Patent number: 6916486Abstract: The present invention provides a transdermal drug delivery system which comprises: a therapeutically effective amount of an analgesic; at least one dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen ester; and at least one volatile liquid. The invention also provides a method for administering at least one systemic acting analgesic to an animal which comprises applying an effective amount of the analgesic in the form of the drug delivery system of the present invention.Type: GrantFiled: May 2, 2003Date of Patent: July 12, 2005Assignee: Acrux DDS PTY LTDInventors: Kathryn Traci-Jane Klose, Felicia Maria Colagrande, Timothy Matthias Morgan, Barrie Charles Finnin, Barry Leonard Reed
-
Patent number: 6916487Abstract: The present invention provides a transdermal drug delivery system which comprises: a therapeutically effective amount of an antiemetic; at least one dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen ester; and at least one volatile liquid. The invention also provides a method for administering at least one systemic acting antiemetic thereof to an animal which comprises applying an effective amount of the antiemetic in the form of the drug delivery system of the present invention.Type: GrantFiled: May 2, 2003Date of Patent: July 12, 2005Assignee: Acrux DDS PTY LTDInventors: Kathryn Traci-Jane Klose, Jianwen Zhou, Timothy Matthias Morgan, Barrie Charles Finnin, Barry Leonard Reed
-
Patent number: 6902740Abstract: The present invention relates to a pressure sensitive adhesive composition comprising a copolymer comprising pyrrolidonoethyl acrylate or pyrrolidonoethyl methacrylate. This composition may be used as part of a transdermal drug delivery device.Type: GrantFiled: July 9, 2001Date of Patent: June 7, 2005Assignee: 3M Innovative Properties CompanyInventors: Mark S. Schaberg, Daniel C. Duan, Kaveh Pournoor
-
Patent number: 6902741Abstract: The transdermal system includes a sex hormone-containing adhesive matrix, which contains inclusions of a sex hormone in a hydrophilic non-crosslinked polymer in dissolved or dispersed form. The inclusions have a concentration of 20 to 90 percent by weight of the sex hormone, which is more than 50 percent by weight amorphous. The hydrophilic non-crosslinked polymer can be polyvinylpyrrolidone, methylcellulose, ethylcellulose or hydroxyethylcellulose. The adhesive matrix can be a polyisobutylene, ethylene-vinyl-acetate copolymer or a polystyrene-butadiene block copolymer.Type: GrantFiled: February 8, 2000Date of Patent: June 7, 2005Assignee: Jenapharm GmbH & Co. KGInventors: Detlef Grawe, Peter Hoesel, Wilfried Fischer
-
Patent number: 6899894Abstract: A transdermal therapeutic system in plaster form for controlled release of oestradiol in combination with norethisterone acetate, comprising a backing layer, a reservoir supersaturated with active ingredients which is attached to said backing layer and prepared using polyacrylate pressure-sensitive adhesives and crystallization inhibitors, and a detachable protective layer, is characterized in that the crystallization inhibitor is an amino-containing polymer.Type: GrantFiled: June 8, 1999Date of Patent: May 31, 2005Assignee: LTS Lohmann Therapie-Systeme AGInventors: Robert Klein, Reinhold Meconi, Walter Müller
-
Patent number: 6899897Abstract: The invention provides a biological dressing for treatment of a dermatological disease comprised of a gum resin, a topically acceptable volatile solvent, and a pharmacologically active agent. The gum resin is present in a suitable amount that the composition, when the solvent evaporates, will dry to form a solid coating that sticks to the skin or mucosal membrane to which the composition is applied and maintain the pharmacologically active agent over a sustained period of time in contact with sites on the skin or mucosal membranes exhibiting symptoms of the disease. Methods are provided for treating symptoms of dermatological diseases with such a pharmacological composition. Biological dressings including tincture of benzoin and clotrimazole are shown to be efficacious for the long-term amelioration of symptoms of athlete's foot.Type: GrantFiled: January 18, 2002Date of Patent: May 31, 2005Assignee: Jaleva, Inc.Inventor: Alex Battaglia
-
Patent number: 6893655Abstract: A transdermal delivery device including at least one pressure sensitive adhesive layer having a first major surface and a second major surface, wherein at least one of the first and second major surfaces is a structured surface; a cap layer in contact with the structured surface of an adhesive layer; and, at least one medicinal ingredient between the adhesive layer and the cap layer.Type: GrantFiled: October 2, 2002Date of Patent: May 17, 2005Assignee: 3M Innovative Properties Co.Inventors: Peggy-Jean P. Flanigan, Hye-ok Choi
-
Patent number: 6893656Abstract: The present invention relates to patches for the administration of an athletic supplement to subjects engaged in rigorous exercise or heavy outdoor work. The invention also relates to methods of administering nutrients to subjects using the patch of the invention.Type: GrantFiled: October 15, 2002Date of Patent: May 17, 2005Assignee: Vita-Patch, LLCInventors: Andrew Blitzer, Terry Pretorius
-
Patent number: 6890553Abstract: The present invention relates to an exothermic device for topically delivering an active agent comprising a liquid reservoir comprising water, a heating element comprising an oxidizable material, an oxygen-permeable outer-layer, an active agent, and a water-impermeable layer, wherein upon the rupturing of the liquid reservoir, the water contacts the heating element and the oxygen to create and exothermic reaction.Type: GrantFiled: July 7, 2000Date of Patent: May 10, 2005Assignee: Johnson & Johnson Consumer Companies, Inc.Inventors: Ying Sun, Ralph W. Oakeson, Stephen J. Wisniewski, Jonas C. T. Wang
-
Patent number: 6890551Abstract: Occlusive plaster consisting of at least one layer of a foam material which is provided on the lower side with a skin-compatible self-adhesive layer.Type: GrantFiled: February 2, 1999Date of Patent: May 10, 2005Assignee: Beiersdorf AGInventors: Dirk Lenz, Robert Mayan, Jürgen Timm, Sebastian Trotter
-
Patent number: 6884434Abstract: A transdermal therapeutic system, comprising a backing layer inert to the components of the matrix, a self-adhesive matrix layer containing (?)-5,6,7,8-tetrahydro-6-[propyl-[2-(2-thienyl)ethyl]amino]-1-naphthalenol in an effective amount and a protective foil or sheet to be removed prior to use, is characterised by a matrix that is based on a non-aqueous, acrylate-based or silicone-based polymer adhesive system having a solubility of ?5% (w/w) for (?)-5,6,7,8-tetrahydro-6-[propyl-[2-(2-thienyl)ethyl]-amino]-1-naphthalenol, and said matrix is substantially free of inorganic silicate particulates.Type: GrantFiled: March 18, 1999Date of Patent: April 26, 2005Assignees: LTS Lohmann Therapie-Systeme AG, Aderis Pharmaceuticals, Inc.Inventors: Walter Muller, James V. Peck
-
Patent number: 6878385Abstract: A dressing for preventing and treating blisters and for treating corns, calluses, warts, and other skin conditions. The dressing has a dressing layer covered by protective cover layer and a release sheet. The dressing has an adhesive composition on a skin-contacting surface. The dressing layer has a thick center portion surrounded by a flange portion. The thick portion has a thickness of less than 1.0 mm. and preferably a thickness of 0.5 mm. The flange portion has a thickness of 0.15 to 0.20 mm. and extends no more than 5.0 mm. from the edge of the thick portion. The configuration of the dressing layer, particularly when used with a hydrocolloid adhesive provides a dressing having wrinkle resistant edges allowing the dressing to be used in areas of the body having high mobility.Type: GrantFiled: January 12, 1999Date of Patent: April 12, 2005Assignee: Jentec, Inc.Inventors: Jarl B. Jensen, Carsten Fredsbo
-
Patent number: 6875444Abstract: A test kit and method for visualizing fine lines and wrinkles is provided, the kit including a transparent strip with an adhesive on one surface thereof and an imaging substrate with at least one darkened glossy area for receiving the transparent strip. Written instructions are provided in the kit. These advise a consumer to place the adhesive surface of the strip against a skin area requiring measurement. Thereafter the strip is removed and placed against the darkened area of the substrate. Topographical features of the skin can be viewed through the transparent strip with the transferred skin image onto the blackened background. A cosmetic anti-aging product can be applied to the skin over a period of time. Beneficial changes caused by the product are visualized through the test strip as periodic measurements are taken.Type: GrantFiled: October 29, 2001Date of Patent: April 5, 2005Assignee: Unilever Home & Personal Care USA, division of Conopco, Inc.Inventors: Josephine Telesca, Liam Anthony Murray, Robert Edward Gott, Craig Stephen Slavtcheff
-
Patent number: 6849665Abstract: Described is a water-absorbent composition containing from 30 to 100% by weight, based on the water-absorbent composition, of water-insoluble water-swellable hydrogels characterized by the following features: Centrifuge Retention Capacity (CRC) of at least 24 g/g, Saline Flow Conductivity (SFC) of at least 80×10?7 cm3 s/g and Free Swell Rate (FSR) of at least 0.15 g/g s and/or Vortex Time of not more than 160 s.Type: GrantFiled: December 28, 2001Date of Patent: February 1, 2005Assignee: BASF AktiengesellschaftInventors: Volker Frenz, Norbert Herfert, Ulrich Riegel, William E. Volz, Thomas H. Majette, James Hill
-
Patent number: 6846837Abstract: Methods and topical pharmaceutical formulations are provided for the treatment of nail fungus (onychomycosis). The invention involves a pharmacologically active antifungal agent, plus a pharmaceutically acceptable base in a formulation having a pH of 7.5 to about 13.0, preferably about 8.0 to 11.5, and most preferably about 8.5 to 10.5. These basic formulations permeate the nail and are effective in treating fungal infections of the nail and surrounding tissues.Type: GrantFiled: June 21, 2002Date of Patent: January 25, 2005Inventors: Howard I. Maibach, Eric C. Luo, Tsung-Min Hsu